Cara Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
TVRD$1.410.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · · · · Additional · · · · · Other · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Accumulated · · Comprehensive · · Stockholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||||||||
| Balance at December 31, 2021 | | 4,456,734 | | $4 | | $708,634 | | $(480,758) | | $(358) | | $227,522 | |||||
| Stock-based compensation expense | | — | | | — | | | 14,345 | | | — | | | — | | | 14,345 |
| Shares issued upon exercise of stock options | | 4,026 | | | — | | | 311 | | | — | | | — | | | 311 |
| Shares issued upon vesting of restricted stock units | | 22,352 | | | — | | | 3,389 | | | — | | | — | | | 3,389 |
| Net loss | | — | | | — | | | — | | | (85,474) | | | — | | | (85,474) |
| Other comprehensive loss | — | | — | | — | | — | | (1,314) | | (1,314) | ||||||
| Balance at December 31, 2022 | | 4,483,112 | | $4 | | $726,679 | | $(566,232) | | $(1,672) | | $158,779 | |||||
| Net proceeds from sales of common stock under open market sales agreement | | 32,240 | | — | | 1,117 | | — | | — | | 1,117 | |||||
| Stock-based compensation expense | | — | | — | | 12,710 | | — | | — | | 12,710 | |||||
| Shares issued upon exercise of stock options | | 7,768 | | 1 | | 559 | | — | | — | | 560 | |||||
| Shares issued upon vesting of restricted stock units | | 16,939 | | — | | 1,020 | | — | | — | | 1,020 | |||||
| Net loss | | — | | | — | | | — | | | (118,513) | | | — | | | (118,513) |
| Other comprehensive income | | — | | — | | — | | — | | 1,412 | | 1,412 | |||||
| Balance at December 31, 2023 | | 4,540,059 | | $5 | | $742,085 | | $(684,745) | | $(260) | | $57,085 | |||||
| Stock-based compensation expense | | — | | | — | | | 6,709 | | | — | | | — | | | 6,709 |
| Shares issued upon vesting of restricted stock units | | 31,170 | | | — | | | 2,220 | | | — | | | — | | | 2,220 |
| Net loss | | — | | | — | | | — | | | (70,867) | | | — | | | (70,867) |
| Other comprehensive income | | — | | | — | | | — | | | — | | | 260 | | | 260 |
| Balance at December 31, 2024 | | 4,571,229 | | $5 | | $751,014 | | $(755,612) | | $— | | $(4,593) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.